Date Title
Sep 06, 2022 Homology Medicines Appoints Albert Seymour, Ph.D., Chief Executive Officer
Aug 15, 2022 Homology Medicines Reports Second Quarter 2022 Financial Results, Recent Highlights and Provides Business Update
Aug 11, 2022 Homology Medicines Announces Optimized, In Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy
Jul 05, 2022 Homology Medicines Announces Peer-Reviewed Publication on Novel Discovery of AAVHSC with Robust Distribution to the Central Nervous System and Peripheral Organs with Low Affinity for the Liver
Jun 29, 2022 Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU
Jun 13, 2022 Homology Medicines Announces FDA Lifted Clinical Hold on pheNIX Gene Therapy Trial for PKU
May 18, 2022 Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression
May 16, 2022 Homology Medicines Reports First Quarter 2022 Financial Results and Recent Highlights
May 02, 2022 Homology Medicines Announces Upcoming Presentation on Optimized In Vivo Gene Editing Candidate HMI-103 with First Details of Unique Mechanism of Action at ASGCT Annual Meeting
Apr 21, 2022 Homology Medicines Announces Promotion of Albert Seymour, Ph.D., to President
Displaying 1 - 10 of 16